{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.3","upperLimit":"21.5","value":"8.7"},{"groupId":"OG001","lowerLimit":"7.9","upperLimit":"59.6","value":"28.6"},{"groupId":"OG002","lowerLimit":"38.9","upperLimit":"69.5","value":"54.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"description":"For AML participants:CR were those with repeat bone marrow showing \\<5% myeloblasts,spicules present and no Auer rods, peripheral blood showing neutrophils\\>=1000/mcL and platelets\\>=100,000/mcL, transfusion independent and no extramedullary disease. For MDS participants:CR were those with repeat bone marrow showing \\<=5% myeloblasts, peripheral blood showing neutrophils\\>=1000/mcL, platelets\\>=100,000/mcL, 0% blast and hemoglobin (Hgb)\\>= 11 g/dL, normal maturation of all cell lines.For AML and MDS participants, complete response with incomplete blood count recovery(CRi)were those with repeat bone marrow showing \\<5% myeloblasts with either platelets or neutrophils not recovered (platelets \\<100,000/mcL or neutrophils \\<1000/mcL).","dispersionType":"80% Confidence Interval","groups":[{"description":"Included all participants who received oral glasdegib in combination with LDAC in phase 1B portion.","id":"OG000","title":"Phase 1B: Glasdegib + LDAC"},{"description":"Included all participants who received oral glasdegib in combination with decitabine in phase 1B portion.","id":"OG001","title":"Phase 1B: Glasdegib + Decitabine"},{"description":"Included all participants who received oral glasdegib in combination with cytarabine/daunorubicin in phase 1B portion.","id":"OG002","title":"Phase 1B: Glasdegib + Cytarabine/Daunorubicin"}],"paramType":"NUMBER","populationDescription":"Full analysis set: all enrolled participants of Phase 1B portion who received at least 1 dose of study medication.","reportingStatus":"POSTED","timeFrame":"4 years","title":"Percentage of Participants With CR / Complete Response With Incomplete Blood Count Recovery (CRi) at Phase 1B","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}